Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
Adds background and Sanders comments in paragraphs 2-8
June 14 (Reuters) -The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk NOVOb.CO CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.
A U.S. Senate health panel vote that was scheduled for its June 18 meeting, to decide whether to subpoena Novo to answer questions about U.S. prices for the blockbuster drugs, is no longer necessary and will be canceled, Senator Bernie Sanders, who chairs the committee, said.
The subpoena would have required Novo President Doug Langa to testify at a July 10 hearing.
Jorgensen will testify before the committee, and the hearing will be held in early September.
Novo charges Americans $1,349 a month for Wegovy, while it can be purchased for $140 in Germany and $92 in the UK, Sanders said.
"The Committee looks forward to Mr. Jorgensen explaining why Americans are paying up to ten or 15 times more for these medications than people in other countries," Sanders added.
In April, Sanders sent a letter to Langa seeking more information on U.S. prices for the two drugs.
Novo responded with a letter in May blaming the U.S. health system for the high prices, according to a report.
Reporting by Puyaan Singh in Bengaluru; Editing by Shounak Dasgupta
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
